Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Heart Risk Findings In Cancer Study Deals Blow To COX-2s

This article was originally published in The Tan Sheet

Executive Summary

Broad regulatory investigations into the COX-2 class could quickly extend to all NSAIDs
Advertisement

Related Content

Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Pfizer COX-2 Marketing, Safety Practices Questioned By DoJ
Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol
Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol
Lack Of FDA Trial Authority, DTC Marketing Caused COX-2 Crisis – Topol
Vioxx Legal Defense: Merck Strategy May Offer Pointers To NSAID Marketers
Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
Vioxx Legal Defense: Merck Strategy May Offer Pointers To NSAID Marketers
Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS097635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel